In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

R&D Productivity Ranking Methodology

Executive Summary

Catenion's methodology for evaluating R&D productivity of the world's 30 largest public pharmaceutical companies, as judged by sales.

You may also be interested in...



Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers

Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.

NICE Decision On Arthritis Opens Door For Biosimilars In England

A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

Granules Records Double-Digit Growth On The Back Of New Launches

India’s Granules has grown through increased market penetration of its existing products as well as new product launches. The company is planning to invest in expanding its API capacity, finished dosages and a new multiple unit pellet facility.

Topics

UsernamePublicRestriction

Register

IV004319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel